Anzeige
Mehr »
Login
Mittwoch, 24.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
SolarBank - Solarenergie...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

PR Newswire-Archiv vom 03.06.2018

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
03.06.18Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea354DUBLIN, June 3, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy...
► Artikel lesen
03.06.18Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy292DUBLIN, June 3, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one...
► Artikel lesen
03.06.18BerGenBio Provides Interim Update on Phase II Clinical Programme With Selective Oral AXL Inhibitor Bemcentinib123CHICAGO, June 3, 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) announces that interim data from its Phase II clinical development programme with bemcentinib, a selective AXL inhibitor, was...
► Artikel lesen
03.06.18Takeda Highlights Favorable Safety Profile of Entyvio (vedolizumab) Through Comparative Real-World Data Versus TNFa-Antagonist Therapy in Ulcerative Colitis and Crohn's Disease163OSAKA, Japan, June 3, 2018 /PRNewswire/ -- Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the...
► Artikel lesen